BULLFROG AI HOLDINGS INC

BFRGNASDAQ

🏆 #4452 by market capUS Equity

$0.61▲ $0.02 (+4.04%)

Live

1h—

24h▲ 4.0%

7d▼ 2.0%

14d▲ 4.8%

30d▼ 9.9%

1y▼ 51.4%

🏦Market Cap

$11M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

92.0%

High

💵FCF Margin

—

⚖️P/S Ratio

1755.3x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $0.61 – $0.62
52-Week Range: $0.43 – $2.04
Volume: $2.59B
Avg Volume: $2.08B
Shares Outstanding: 18.5M
Next Earnings: Oct 21, 2026

Fundamentals Snapshot

Annual Revenue: $116,670
Last Q Revenue: $28,234
P/E Ratio: —
P/S Ratio: 1755.3x
EPS (TTM): $-0.55
Dividend Yield: —

Why Investors Own BFRG

✓High-growth profile — revenue up +30.8% YoY with expanding US Equity exposure.
✓Healthy economics — 43% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$116,670▲ +32.1% YoY

Gross Margin (TTM)

43.2%▲ +2.7% YoY

Operating Income (TTM)

$13,184▲ +32.1% YoY

Free Cash Flow (TTM)

$16,217▲ +32.1% YoY

About BULLFROG AI HOLDINGS INC

BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.

🦦